Aditya Bardia, MD, MPH, Dana-Farber Harvard Cancer Center

Perioperative Therapy: ASCO 2020 Data Updates

August 13th 2020

Metastatic Triple-Negative Breast Cancer Ongoing Trials

August 13th 2020

ASCO 2020 Data Updates: Metastatic HER2+ Breast Cancer

August 13th 2020

Metastatic HR+ Breast Cancer Updates

August 13th 2020

Dr. Bardia on the Potential Impact of COVID-19 on Immunocompromised Patients

March 18th 2020

Aditya Bardia, MD, MPH, discusses the potential impact of novel coronavirus on immunocompromised patients.

Dr. Bardia on the Clinical Utility of Liquid Biopsies in Breast Cancer

February 12th 2020

Aditya Bardia, MD, MPH, discusses the clinical utility of liquid biopsies in breast cancer.

Dr. Bardia Discusses the Skepticism Regarding Biosimilars in Oncology

August 28th 2019

Aditya Bardia, MD, MPH, director of Precision Medicine at the Center for Breast Cancer, Massachusetts General Hospital Cancer Center, and assistant professor of medicine, Harvard Medical School, discusses the skepticism regarding biosimilars in oncology.

Dr. Bardia on Sacituzumab Govitecan in TNBC

March 26th 2019

Aditya Bardia, MD, MPH, director of Precision Medicine at the Center for Breast Cancer, Massachusetts General Hospital Cancer Center, and assistant professor of medicine, Harvard Medical School, discusses the potential of sacituzumab govitecan in patients with triple-negative breast cancer (TNBC).

Circulating Tumor DNA Testing Shows Growing Potential for Clinical Utility in Breast Cancer

March 12th 2019

CtDNA will continue to gain importance in precision oncology as physicians continue to uncover the role and interplay of genomic alterations that promote tumor heterogeneity.

Dr. Bardia on Potential Concerns With Biosimilars in Breast Cancer

December 11th 2018

Aditya Bardia, MD, MPH, director of Precision Medicine at the Center for Breast Cancer, Massachusetts General Hospital Cancer Center, Harvard Medical School, discusses potential concerns regarding the use of biosimilars in the breast cancer space.

Dr. Bardia on the Role of the Microenvironment in TNBC

February 17th 2018

Aditya Bardia, MD, MPH, assistant professor of medicine, Harvard Medical School, attending physician, Medical Oncology, Massachusetts General Hospital, discusses the role of the microenvironment in the treatment of metastatic triple-negative breast cancer (TNBC).

Dr. Bardia on Sacituzumab Govitecan in Triple-Negative Breast Cancer

January 31st 2018

Aditya Bardia, MD, MPH, assistant professor of medicine, Harvard Medical School, attending physician, Medical Oncology, Massachusetts General Hospital, discusses a trial investigating sacituzumab govitecan for patients with triple-negative breast cancer (TNBC).

Dr. Aditya Bardia on RAD1901 in ER-Positive Metastatic Breast Cancer

January 29th 2016

Aditya Bardia, MD, MPH, assistant professor of Medicine, Harvard Medical School, attending physician, Medical Oncology, Massachusetts General Hospital, discusses RAD1901, a selective estrogen receptor degrader (SERD) for potential use in ER-positive metastatic breast cancer.